ATE548381T1 - Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus - Google Patents

Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus

Info

Publication number
ATE548381T1
ATE548381T1 AT09765524T AT09765524T ATE548381T1 AT E548381 T1 ATE548381 T1 AT E548381T1 AT 09765524 T AT09765524 T AT 09765524T AT 09765524 T AT09765524 T AT 09765524T AT E548381 T1 ATE548381 T1 AT E548381T1
Authority
AT
Austria
Prior art keywords
polypeptides
epo
pharmaceutical compositions
protease resistance
modified
Prior art date
Application number
AT09765524T
Other languages
English (en)
Inventor
Thierry Guyon
Gilles Borrelly
Xavier Gallet
Lila Drittanti
Manuel Vega
Original Assignee
Hanall Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Biopharma Co Ltd filed Critical Hanall Biopharma Co Ltd
Application granted granted Critical
Publication of ATE548381T1 publication Critical patent/ATE548381T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT09765524T 2008-05-29 2009-05-29 Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus ATE548381T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13037608P 2008-05-29 2008-05-29
PCT/EP2009/003862 WO2009152944A1 (en) 2008-05-29 2009-05-29 Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ATE548381T1 true ATE548381T1 (de) 2012-03-15

Family

ID=40943614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09765524T ATE548381T1 (de) 2008-05-29 2009-05-29 Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus

Country Status (7)

Country Link
US (1) US20120264686A9 (de)
EP (1) EP2297197B1 (de)
JP (1) JP2011520472A (de)
KR (1) KR101275950B1 (de)
CN (1) CN102186879A (de)
AT (1) ATE548381T1 (de)
WO (1) WO2009152944A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP2120998B1 (de) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modifizierte erythropoetin-polypeptide und ihre verwendungen zur behandlung
IN2012DN05145A (de) * 2009-11-19 2015-10-23 Solis Biodyne
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN107022032A (zh) 2011-01-19 2017-08-08 菲卢马克斯制药公司 用于调节铁稳态的组合物及其使用方法
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (de) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3194429A4 (de) * 2014-09-18 2018-06-13 Askgene Pharma, Inc. Neuartige feline erythropoietinrezeptor-agonisten
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR101947342B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Gm-csf 반감기를 증가시키는 방법
CN107898812A (zh) * 2017-12-06 2018-04-13 广州瑞铂茵健康管理咨询有限公司 一种基于脐带干细胞及活性成分的软骨损伤混合修复液
CN110093336B (zh) * 2018-01-29 2023-03-24 上海雅心生物技术有限公司 一种稳定的胰蛋白酶及其制备方法
US12089930B2 (en) 2018-03-05 2024-09-17 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
CN110241130B (zh) * 2018-03-09 2023-04-14 中国科学院分子植物科学卓越创新中心 控制植物粒数和粒重的gsn1基因、编码蛋白及其应用
AR113091A1 (es) * 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
US20230151071A1 (en) * 2020-04-09 2023-05-18 United States Government As Represented By The Department Of Veterans Affairs Compositions comprising recombinant epo and methods of use thereof
US20230405086A1 (en) * 2020-05-01 2023-12-21 Icahn School Of Medicine At Mount Sinai Compositions and methods for preventing, detecting, and treating inflammatory bowel disease
US11566056B2 (en) 2020-05-26 2023-01-31 Sylus Co., Ltd Peptide and use thereof for treatment of disease of brain and nervous system
MX2023003700A (es) * 2020-09-30 2023-04-21 Realta Life Sciences Inc Peptidos y metodos de uso.
US20240109946A1 (en) * 2020-11-18 2024-04-04 Chulabhorn Foundation Erythropoietin variants and uses thereof
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
WO2023222040A1 (zh) * 2022-05-17 2023-11-23 广州汉腾生物科技有限公司 重组促红细胞生成素及其应用
CN116732012A (zh) * 2023-03-13 2023-09-12 山东舜丰生物科技有限公司 碱基编辑器及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03151399A (ja) * 1989-11-07 1991-06-27 Snow Brand Milk Prod Co Ltd 変異ヒトエリスロポエチン
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
BR0207015A (pt) * 2001-02-06 2004-07-06 Merck Patent Ges Mit Beschroen Eritropoientina modificada (epo) com imunogenicidade reduzida
AU2002351746A1 (en) * 2001-12-21 2003-07-15 Maxygen Aps Erythropoietin conjugates
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20060020396A1 (en) 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
WO2004022747A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20050202438A1 (en) 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
CN100405906C (zh) * 2002-10-09 2008-07-30 尼奥斯技术有限公司 促红细胞生成素:促红细胞生成素的重构和糖缀合
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants
US20060073563A1 (en) * 2004-09-02 2006-04-06 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
GB0500099D0 (en) * 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
EP2120998B1 (de) * 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modifizierte erythropoetin-polypeptide und ihre verwendungen zur behandlung
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides

Also Published As

Publication number Publication date
KR101275950B1 (ko) 2013-06-25
JP2011520472A (ja) 2011-07-21
US20120264686A9 (en) 2012-10-18
US20120094906A1 (en) 2012-04-19
WO2009152944A1 (en) 2009-12-23
EP2297197A1 (de) 2011-03-23
CN102186879A (zh) 2011-09-14
EP2297197B1 (de) 2012-03-07
KR20110022638A (ko) 2011-03-07

Similar Documents

Publication Publication Date Title
WO2008065372A3 (en) Modified erythropoietin polypeptides and uses thereof for treatment
JOP20190083B1 (ar) بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EA201171220A1 (ru) Мутанты fgf21 и их применение
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
EP2568996A4 (de) Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen
NO20082531L (no) Neuropilinantagonister
EP2563912A4 (de) Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von asparaginyl-trna-synthetasen
BRPI0609797B8 (pt) nanocorpos melhorados para o tratamento de desordens mediadas por agregação
BR112014022708A8 (pt) uso de uma proteína ligante de neurotrofina p75ntr, uso de uma molécula de ácido nucleico, uso de um vetor de expressão replicável, célula hospedeira, composição farmacêutica e kit
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
CL2007003629A1 (es) Compuestos heterociclicos aril-sustituidos, moduladores del receptor de cannabinoides tipo i (cb1); proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos metabolicos y trastornos cognitivos.
WO2007133835A8 (en) Ras mutation and compositions and methods related thereto
EP2566516A4 (de) Innovative entdeckung von therapeutischen und diagnostischen mitteln sowie antikörperzusammensetzungen im zusammenhang mit proteinfragmenten von seryl-trna-synthetasen
TR201908638T4 (tr) Ang2 bağlayıcı moleküller.
EA201101523A1 (ru) Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EP2563911A4 (de) Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von alanyl-trna-synthetasen
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
MX2009002816A (es) Proteinas de fusion de albumina.
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
MX374682B (es) Moléculas de unión a 4-1bb.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX385926B (es) Proteínas de fusión de citoquinas.